These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20818470)

  • 1. Implications of the Impact Survey for payors across Europe.
    Forette F; Padovani A; Berthet K; Knox S
    J Nutr Health Aging; 2010 Aug; 14(7):553-7. PubMed ID: 20818470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for cognitive impairment, Alzheimer's disease and other dementias: opinions of European caregivers, payors, physicians and the general public.
    Bond J; Graham N; Padovani A; Mackell J; Knox S; Atkinson J
    J Nutr Health Aging; 2010 Aug; 14(7):558-62. PubMed ID: 20818471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing attitudes and behaviours surrounding Alzheimer's disease in Europe: key findings of the Important Perspectives on Alzheimer's Care and Treatment (IMPACT) survey.
    Jones RW; Mackell J; Berthet K; Knox S
    J Nutr Health Aging; 2010 Aug; 14(7):525-30. PubMed ID: 20818466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving attitudes to Alzheimer's disease among the general public and caregivers in Europe: findings from the IMPACT survey.
    Wortmann M; Andrieu S; Mackell J; Knox S
    J Nutr Health Aging; 2010 Aug; 14(7):531-6. PubMed ID: 20818467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the Facing Dementia Survey for health care professionals across Europe.
    Wilkinson D; Sganga A; Stave C; O'Connell B
    Int J Clin Pract Suppl; 2005 Mar; (146):27-31. PubMed ID: 15801189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing physician attitudes and perceptions of Alzheimer's disease across Europe.
    Martinez-Lage P; Frolich L; Knox S; Berthet K
    J Nutr Health Aging; 2010 Aug; 14(7):537-44. PubMed ID: 20818468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential Impact of Alzheimer's Disease Early Treatment on Societal Costs of Care in Czechia: A Simulation Approach.
    Broulikova HM; Sladek V; Arltova M; Cerny J
    J Ment Health Policy Econ; 2018 Dec; 21(4):147-161. PubMed ID: 30676992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the Facing Dementia Survey for policy makers and third-party organisations across Europe.
    Rimmer E; Stave C; Sganga A; O'Connell B
    Int J Clin Pract Suppl; 2005 Mar; (146):34-8. PubMed ID: 15801191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The macroeconomics of dementia--will the world economy get Alzheimer's disease?
    Banerjee S
    Arch Med Res; 2012 Nov; 43(8):705-9. PubMed ID: 23085453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicians and caregivers: ready and waiting for increased participation in clinical research.
    Jones RW; Andrieu S; Knox S; Mackell J
    J Nutr Health Aging; 2010 Aug; 14(7):563-8. PubMed ID: 20818472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey.
    Bond J; Stave C; Sganga A; O'Connell B; Stanley RL
    Int J Clin Pract Suppl; 2005 Mar; (146):8-14. PubMed ID: 15801185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes.
    Weimer DL; Sager MA
    Alzheimers Dement; 2009 May; 5(3):215-26. PubMed ID: 19362885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America.
    Takizawa C; Thompson PL; van Walsem A; Faure C; Maier WC
    J Alzheimers Dis; 2015; 43(4):1271-84. PubMed ID: 25159675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of Alzheimer's disease in managed care: a cross-sectional study.
    Leon J; Neumann PJ
    Am J Manag Care; 1999 Jul; 5(7):867-77. PubMed ID: 10557408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The UP-TECH project, an intervention to support caregivers of Alzheimer's disease patients in Italy: study protocol for a randomized controlled trial.
    Chiatti C; Masera F; Rimland JM; Cherubini A; Scarpino O; Spazzafumo L; Lattanzio F;
    Trials; 2013 May; 14():155. PubMed ID: 23714287
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.